These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34294894)

  • 1. Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer.
    Hickey TE; Dwyer AR; Tilley WD
    Br J Cancer; 2021 Dec; 125(12):1599-1601. PubMed ID: 34294894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
    Wei L; Gao H; Yu J; Zhang H; Nguyen TTL; Gu Y; Passow MR; Carter JM; Qin B; Boughey JC; Goetz MP; Weinshilboum RM; Ingle JN; Wang L
    Cancer Res; 2023 Feb; 83(3):456-470. PubMed ID: 36469363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting androgen receptor in estrogen receptor-negative breast cancer.
    Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Liu XS; Brown M
    Cancer Cell; 2011 Jul; 20(1):119-31. PubMed ID: 21741601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pushing estrogen receptor around in breast cancer.
    Lim E; Tarulli G; Portman N; Hickey TE; Tilley WD; Palmieri C
    Endocr Relat Cancer; 2016 Dec; 23(12):T227-T241. PubMed ID: 27729416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
    Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
    Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting Androgen Receptor Signaling in Breast Cancer.
    Dai C; Ellisen LW
    Oncologist; 2023 May; 28(5):383-391. PubMed ID: 36972361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.
    Basile D; Cinausero M; Iacono D; Pelizzari G; Bonotto M; Vitale MG; Gerratana L; Puglisi F
    Cancer Treat Rev; 2017 Dec; 61():15-22. PubMed ID: 29078133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone receptors in breast cancer: more than estrogen receptors.
    Lamb CA; Vanzulli SI; Lanari C
    Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
    Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer.
    Tokunaga E; Hisamatsu Y; Taketani K; Yamashita N; Akiyoshi S; Okada S; Tanaka K; Saeki H; Oki E; Aishima S; Oda Y; Morita M; Maehara Y
    Cancer Med; 2013 Dec; 2(6):763-73. PubMed ID: 24403250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma.
    Fujii R; Hanamura T; Suzuki T; Gohno T; Shibahara Y; Niwa T; Yamaguchi Y; Ohnuki K; Kakugawa Y; Hirakawa H; Ishida T; Sasano H; Ohuchi N; Hayashi S
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():513-22. PubMed ID: 25178713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
    D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
    Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
    Nahleh Z
    Future Oncol; 2008 Feb; 4(1):15-21. PubMed ID: 18240997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the androgen receptor in triple-negative breast cancer.
    Shah PD; Gucalp A; Traina TA
    Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer.
    Vontela N; Koduri V; Schwartzberg LS; Vidal GA
    J Natl Compr Canc Netw; 2017 Mar; 15(3):284-287. PubMed ID: 28275030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
    Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.